{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T18:47:06Z","timestamp":1778611626309,"version":"3.51.4"},"reference-count":304,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T00:00:00Z","timestamp":1572912000000},"content-version":"vor","delay-in-days":1191,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1093\/annonc\/mdw235","type":"journal-article","created":{"date-parts":[[2016,7,5]],"date-time":"2016-07-05T21:10:10Z","timestamp":1467753010000},"page":"1386-1422","source":"Crossref","is-referenced-by-count":2858,"title":["ESMO consensus guidelines for the management of patients with metastatic colorectal cancer"],"prefix":"10.1016","volume":"27","author":[{"given":"E.","family":"Van Cutsem","sequence":"first","affiliation":[]},{"given":"A.","family":"Cervantes","sequence":"additional","affiliation":[]},{"given":"R.","family":"Adam","sequence":"additional","affiliation":[]},{"given":"A.","family":"Sobrero","sequence":"additional","affiliation":[]},{"given":"J.H.","family":"Van Krieken","sequence":"additional","affiliation":[]},{"given":"D.","family":"Aderka","sequence":"additional","affiliation":[]},{"given":"E.","family":"Aranda Aguilar","sequence":"additional","affiliation":[]},{"given":"A.","family":"Bardelli","sequence":"additional","affiliation":[]},{"given":"A.","family":"Benson","sequence":"additional","affiliation":[]},{"given":"G.","family":"Bodoky","sequence":"additional","affiliation":[]},{"given":"F.","family":"Ciardiello","sequence":"additional","affiliation":[]},{"given":"A.","family":"D'Hoore","sequence":"additional","affiliation":[]},{"given":"E.","family":"Diaz-Rubio","sequence":"additional","affiliation":[]},{"given":"J.-Y.","family":"Douillard","sequence":"additional","affiliation":[]},{"given":"M.","family":"Ducreux","sequence":"additional","affiliation":[]},{"given":"A.","family":"Falcone","sequence":"additional","affiliation":[]},{"given":"A.","family":"Grothey","sequence":"additional","affiliation":[]},{"given":"T.","family":"Gruenberger","sequence":"additional","affiliation":[]},{"given":"K.","family":"Haustermans","sequence":"additional","affiliation":[]},{"given":"V.","family":"Heinemann","sequence":"additional","affiliation":[]},{"given":"P.","family":"Hoff","sequence":"additional","affiliation":[]},{"given":"C.-H.","family":"K\u00f6hne","sequence":"additional","affiliation":[]},{"given":"R.","family":"Labianca","sequence":"additional","affiliation":[]},{"given":"P.","family":"Laurent-Puig","sequence":"additional","affiliation":[]},{"given":"B.","family":"Ma","sequence":"additional","affiliation":[]},{"given":"T.","family":"Maughan","sequence":"additional","affiliation":[]},{"given":"K.","family":"Muro","sequence":"additional","affiliation":[]},{"given":"N.","family":"Normanno","sequence":"additional","affiliation":[]},{"given":"P.","family":"\u00d6sterlund","sequence":"additional","affiliation":[]},{"given":"W.J.G.","family":"Oyen","sequence":"additional","affiliation":[]},{"given":"D.","family":"Papamichael","sequence":"additional","affiliation":[]},{"given":"G.","family":"Pentheroudakis","sequence":"additional","affiliation":[]},{"given":"P.","family":"Pfeiffer","sequence":"additional","affiliation":[]},{"given":"T.J.","family":"Price","sequence":"additional","affiliation":[]},{"given":"C.","family":"Punt","sequence":"additional","affiliation":[]},{"given":"J.","family":"Ricke","sequence":"additional","affiliation":[]},{"given":"A.","family":"Roth","sequence":"additional","affiliation":[]},{"given":"R.","family":"Salazar","sequence":"additional","affiliation":[]},{"given":"W.","family":"Scheithauer","sequence":"additional","affiliation":[]},{"given":"H.J.","family":"Schmoll","sequence":"additional","affiliation":[]},{"given":"J.","family":"Tabernero","sequence":"additional","affiliation":[]},{"given":"J.","family":"Ta\u00efeb","sequence":"additional","affiliation":[]},{"given":"S.","family":"Tejpar","sequence":"additional","affiliation":[]},{"given":"H.","family":"Wasan","sequence":"additional","affiliation":[]},{"given":"T.","family":"Yoshino","sequence":"additional","affiliation":[]},{"given":"A.","family":"Zaanan","sequence":"additional","affiliation":[]},{"given":"D.","family":"Arnold","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdw235_bb0010","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012","volume":"49","author":"Ferlay","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdw235_bb0015","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdw235_bb0020","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1093\/annonc\/mds236","article-title":"ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making","volume":"23","author":"Schmoll","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0025","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1086\/321805","article-title":"Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients","volume":"33","author":"Dykewicz","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"Suppl 3","key":"10.1093\/annonc\/mdw235_bb0030","doi-asserted-by":"crossref","first-page":"iii1","DOI":"10.1093\/annonc\/mdu260","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Van Cutsem","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0035","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1093\/jnci\/djs438","article-title":"Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues","volume":"104","author":"Neumeister","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdw235_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/modpathol.2012.123","article-title":"Delay to formalin fixation \u2018cold ischemia time\u2019: effect on ERBB2 detection by in-situ hybridization and immunohistochemistry","volume":"26","author":"Portier","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1093\/annonc\/mdw235_bb0045","doi-asserted-by":"crossref","first-page":"537","DOI":"10.5858\/2010-0702-RAIR.1","article-title":"Effects of preanalytical variables on the detection of proteins by immunohistochemistry in formalin-fixed, paraffin-embedded tissue","volume":"135","author":"Engel","year":"2011","journal-title":"Arch Pathol Lab Med"},{"key":"10.1093\/annonc\/mdw235_bb0050","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00129039-200206000-00015","article-title":"Effect of prolonged formalin fixation on the immunohistochemical reactivity of breast markers","volume":"10","author":"Arber","year":"2002","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1093\/annonc\/mdw235_bb0055","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ymeth.2010.08.012","article-title":"The impact of pre-analytical processing on staining quality for H&E, dual hapten, dual color in situ hybridization and fluorescent in situ hybridization assays","volume":"52","author":"Babic","year":"2010","journal-title":"Methods"},{"key":"10.1093\/annonc\/mdw235_bb0060","doi-asserted-by":"crossref","first-page":"e54138","DOI":"10.1371\/journal.pone.0054138","article-title":"Rapid two-temperature formalin fixation","volume":"8","author":"Chafin","year":"2013","journal-title":"PLoS One"},{"key":"10.1093\/annonc\/mdw235_bb0065","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1093\/annonc\/mdu145","article-title":"Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer","volume":"25","author":"Kerr","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0070","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00428-008-0665-y","article-title":"KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program","volume":"453","author":"van Krieken","year":"2008","journal-title":"Virchows Arch"},{"key":"10.1093\/annonc\/mdw235_bb0075","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00428-012-1356-2","article-title":"KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance","volume":"462","author":"Dijkstra","year":"2013","journal-title":"Virchows Arch"},{"key":"10.1093\/annonc\/mdw235_bb0080","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2353\/jmoldx.2010.090188","article-title":"Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications","volume":"12","author":"Tsiatis","year":"2010","journal-title":"J Mol Diagn"},{"key":"10.1093\/annonc\/mdw235_bb0085","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.2217\/pgs.10.86","article-title":"Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR\/sequencing and real-time PCR approach","volume":"11","author":"Carotenuto","year":"2010","journal-title":"Pharmacogenomics"},{"key":"10.1093\/annonc\/mdw235_bb0090","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1111\/j.1582-4934.2009.00788.x","article-title":"High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue","volume":"14","author":"Tol","year":"2010","journal-title":"J Cell Mol Med"},{"key":"10.1093\/annonc\/mdw235_bb0095","doi-asserted-by":"crossref","first-page":"4830","DOI":"10.1158\/1078-0432.CCR-07-4906","article-title":"K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy","volume":"14","author":"Etienne-Grimaldi","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw235_bb0100","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/0959-8049(92)90468-H","article-title":"Stability of K-ras mutations throughout the natural history of human colorectal cancer","volume":"28A","author":"Losi","year":"1992","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdw235_bb0105","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ijc.2910520107","article-title":"K-ras point mutations in human colorectal carcinomas: relation to aneuploidy and metastasis","volume":"52","author":"Suchy","year":"1992","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdw235_bb0110","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/ijc.22343","article-title":"Allelotyping analyses of synchronous primary and metastasis CIN colon cancers identified different subtypes","volume":"120","author":"Weber","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdw235_bb0115","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/mp.56.3.137","article-title":"Molecular changes in the Ki-ras and APC genes in primary colorectal carcinoma and synchronous metastases compared with the findings in accompanying adenomas","volume":"56","author":"Zauber","year":"2003","journal-title":"Mol Pathol"},{"key":"10.1093\/annonc\/mdw235_bb0120","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/ijc.2910490613","article-title":"Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver","volume":"49","author":"Oudejans","year":"1991","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdw235_bb0125","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/(SICI)1096-9896(199806)185:2<130::AID-PATH85>3.0.CO;2-M","article-title":"Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality","volume":"185","author":"Al-Mulla","year":"1998","journal-title":"J Pathol"},{"key":"10.1093\/annonc\/mdw235_bb0130","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.bbrc.2004.10.111","article-title":"Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations","volume":"325","author":"Albanese","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1093\/annonc\/mdw235_bb0135","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/sj.onc.1209758","article-title":"KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression","volume":"26","author":"Oliveira","year":"2007","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mdw235_bb0140","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1200\/JCO.2008.18.7286","article-title":"Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer","volume":"26","author":"Artale","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0145","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1634\/theoncologist.2008-0181","article-title":"High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice","volume":"13","author":"Santini","year":"2008","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdw235_bb0150","doi-asserted-by":"crossref","first-page":"e8199","DOI":"10.1371\/journal.pone.0008199","article-title":"KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis","volume":"4","author":"Cejas","year":"2009","journal-title":"PLoS One"},{"key":"10.1093\/annonc\/mdw235_bb0155","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/annonc\/mdn712","article-title":"The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer","volume":"20","author":"Garm Spindler","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0160","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1200\/JCO.2008.20.2796","article-title":"PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer","volume":"27","author":"Loupakis","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0165","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/sj.bjc.6604848","article-title":"Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant","volume":"100","author":"Molinari","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdw235_bb0170","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/annonc\/mdn541","article-title":"PI3KCA\/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients","volume":"20","author":"Perrone","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0175","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1158\/1078-0432.CCR-09-2446","article-title":"Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases","volume":"16","author":"Baldus","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw235_bb0180","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1245\/s10434-009-0864-z","article-title":"KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications","volume":"17","author":"Italiano","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0185","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/bjc.2011.26","article-title":"KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients","volume":"104","author":"Knijn","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdw235_bb0190","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/2159-8290.CD-11-0341","article-title":"EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib","volume":"2","author":"Corcoran","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1093\/annonc\/mdw235_bb0195","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(11)60613-2","article-title":"Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial","volume":"377","author":"Maughan","year":"2011","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdw235_bb0200","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw235_bb0205","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1158\/1078-0432.CCR-09-2167","article-title":"Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents","volume":"16","author":"Dancey","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw235_bb0210","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","article-title":"Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer","volume":"26","author":"Amado","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0215","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","article-title":"K-ras mutations and benefit from cetuximab in advanced colorectal cancer","volume":"359","author":"Karapetis","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw235_bb0220","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"Van Cutsem","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw235_bb0225","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","article-title":"Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status","volume":"29","author":"Van Cutsem","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0230","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1200\/JCO.2008.20.8397","article-title":"Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer","volume":"27","author":"Bokemeyer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0235","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/annonc\/mdq632","article-title":"Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study","volume":"22","author":"Bokemeyer","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0240","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1200\/JCO.2009.27.6055","article-title":"Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer","volume":"28","author":"Peeters","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0245","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","article-title":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer","volume":"369","author":"Douillard","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw235_bb0250","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1200\/JCO.2014.59.4812","article-title":"Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer","volume":"33","author":"Van Cutsem","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0255","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.ejca.2015.04.007","article-title":"FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer","volume":"51","author":"Bokemeyer","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdw235_bb0260","doi-asserted-by":"crossref","first-page":"5469","DOI":"10.1158\/1078-0432.CCR-15-0526","article-title":"Analysis of KRAS\/NRAS mutations in a Phase III Study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer","volume":"21","author":"Peeters","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw235_bb0265","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s11523-013-0271-z","article-title":"An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer","volume":"8","author":"Poulin-Costello","year":"2013","journal-title":"Target Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0270","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2013.53.2473","volume":"32","author":"Schwartzberg","year":"2014","journal-title":"J Clin Oncol"},{"issue":"3 Suppl","key":"10.1093\/annonc\/mdw235_bb0275","article-title":"Mutations within the EGFR signaling pathway: influence on efficacy in FIRE-3\u2014a randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients","volume":"32","author":"Stintzing","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0280","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial","volume":"15","author":"Heinemann","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0285","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/annonc\/mdu378","article-title":"Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials","volume":"26","author":"Sorich","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0290","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1136\/jclinpath-2014-202467","article-title":"RAS testing of colorectal carcinoma\u2014a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group","volume":"67","author":"Wong","year":"2014","journal-title":"J Clin Pathol"},{"key":"10.1093\/annonc\/mdw235_bb0295","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1634\/theoncologist.2014-0382","article-title":"External quality assessment unravels interlaboratory differences in quality of RAS testing for anti-EGFR therapy in colorectal cancer","volume":"20","author":"Tack","year":"2015","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdw235_bb0300","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1634\/theoncologist.2014-0252","article-title":"Cost estimates and economic implications of expanded RAS testing in metastatic colorectal cancer","volume":"20","author":"Kircher","year":"2015","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdw235_bb0305","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1002\/cncr.26086","article-title":"Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer","volume":"117","author":"Tran","year":"2011","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdw235_bb0310","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1200\/JCO.2011.38.0915","article-title":"Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study","volume":"30","author":"Tveit","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0315","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.1158\/1078-0432.CCR-14-0332","article-title":"Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies","volume":"20","author":"Venderbosch","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw235_bb0320","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1056\/NEJMc0904160","article-title":"BRAF mutation in metastatic colorectal cancer","volume":"361","author":"Tol","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw235_bb0325","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1158\/1078-0432.CCR-12-1913","article-title":"Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer","volume":"19","author":"Peeters","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw235_bb0330","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S1470-2045(13)70163-3","article-title":"Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial","volume":"14","author":"Seymour","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0335","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ejca.2015.01.054","article-title":"Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis","volume":"51","author":"Pietrantonio","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdw235_bb0340","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1038\/bjc.2015.173","article-title":"Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer","volume":"112","author":"Rowland","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdw235_bb0345","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","article-title":"FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study","volume":"16","author":"Cremolini","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0350","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw235_bb0355","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1200\/JCO.2015.63.2497","article-title":"Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer","volume":"33","author":"Kopetz","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0360","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature10868","article-title":"Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR","volume":"483","author":"Prahallad","year":"2012","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdw235_bb0365","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1200\/JCO.2015.63.2471","article-title":"Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer","volume":"33","author":"Corcoran","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0370","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw235_bb0375","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1158\/1078-0432.CCR-06-3064","article-title":"Distinction of hereditary nonpolyposis colorectal cancer and sporadic microsatellite-unstable colorectal cancer through quantification of MLH1 methylation by real-time PCR","volume":"13","author":"Bettstetter","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw235_bb0380","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1038\/sj.onc.1208569","article-title":"BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes","volume":"24","author":"Domingo","year":"2005","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mdw235_bb0385","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10689-007-9124-1","article-title":"Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer","volume":"6","author":"Loughrey","year":"2007","journal-title":"Fam Cancer"},{"key":"10.1093\/annonc\/mdw235_bb0390","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1093\/annonc\/mdv290","article-title":"BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis","volume":"26","author":"Cremolini","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0395","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11523-008-0103-8","article-title":"Microsatellite instability: a predictive marker in metastatic colorectal cancer?","volume":"4","author":"Des Guetz","year":"2009","journal-title":"Target Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0400","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1093\/annonc\/mdu100","article-title":"Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H)","volume":"25","author":"Goldstein","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0405","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00384-008-0504-2","article-title":"Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group","volume":"23","author":"Muller","year":"2008","journal-title":"Int J Colorectal Dis"},{"key":"10.1093\/annonc\/mdw235_bb0410","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1055\/s-0034-1366781","article-title":"Prognostic value of microsatellite instability and p53 expression in metastatic colorectal cancer treated with oxaliplatin and fluoropyrimidine-based chemotherapy","volume":"52","author":"Nopel-Dunnebacke","year":"2014","journal-title":"Z Gastroenterol"},{"key":"10.1093\/annonc\/mdw235_bb0415","first-page":"2715","article-title":"Microsatellite instability and sensitivitiy to FOLFOX treatment in metastatic colorectal cancer","volume":"27","author":"des Guetz","year":"2007","journal-title":"Anticancer Res"},{"key":"10.1093\/annonc\/mdw235_bb0420","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1111\/j.1349-7006.2011.02009.x","article-title":"Association between deficient mismatch repair system and efficacy to irinotecan-containing chemotherapy in metastatic colon cancer","volume":"102","author":"Kim","year":"2011","journal-title":"Cancer Sci"},{"key":"10.1093\/annonc\/mdw235_bb0425","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw235_bb0430","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1053\/j.scrs.2008.09.007","article-title":"Predictive factors for response and toxicity in chemotherapy: pharmacogenomics","volume":"19","author":"Sanoff","year":"2008","journal-title":"Semin Colon Rectal Surg"},{"key":"10.1093\/annonc\/mdw235_bb0435","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/S1470-2045(15)00286-7","article-title":"Clinical relevance of DPYD variants c.1679T>G, c.1236G>A\/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data","volume":"16","author":"Meulendijks","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0440","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.2217\/pgs.10.95","article-title":"Irinotecan pharmacogenomics","volume":"11","author":"Marsh","year":"2010","journal-title":"Pharmacogenomics"},{"key":"10.1093\/annonc\/mdw235_bb0445","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/FPC.0000000000000024","article-title":"PharmGKB summary: very important pharmacogene information for UGT1A1","volume":"24","author":"Barbarino","year":"2014","journal-title":"Pharmacogenet Genomics"},{"key":"10.1093\/annonc\/mdw235_bb0450","series-title":"Camptosar prescribing information","year":"2014"},{"key":"10.1093\/annonc\/mdw235_bb0455","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/MCP.0b013e32816b5c63","article-title":"ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer","volume":"13","author":"Olaussen","year":"2007","journal-title":"Curr Opin Pulm Med"},{"key":"10.1093\/annonc\/mdw235_bb0460","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1200\/JCO.2007.11.3167","article-title":"ERCC1-tailored chemotherapy in lung cancer: the first prospective randomized trial","volume":"25","author":"Soria","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0465","doi-asserted-by":"crossref","first-page":"8383","DOI":"10.7314\/APJCP.2014.15.19.8383","article-title":"The ERCC1 C118T polymorphism predicts clinical outcomes of colorectal cancer patients receiving oxaliplatin-based chemotherapy: a meta-analysis based on 22 studies","volume":"15","author":"Qian","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1093\/annonc\/mdw235_bb0470","doi-asserted-by":"crossref","first-page":"70","DOI":"10.7150\/jca.10478","article-title":"ERCC1 induction after oxaliplatin exposure may depend on KRAS mutational status in colorectal cancer cell line: in vitro veritas","volume":"6","author":"Orlandi","year":"2015","journal-title":"J Cancer"},{"key":"10.1093\/annonc\/mdw235_bb0475","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0925-4439(02)00082-0","article-title":"Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism","volume":"1587","author":"Peters","year":"2002","journal-title":"Biochim Biophys Acta"},{"key":"10.1093\/annonc\/mdw235_bb0480","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/jnci\/djm115","article-title":"UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters","volume":"99","author":"Hoskins","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdw235_bb0485","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1158\/2159-8290.CD-14-0462","article-title":"Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution","volume":"4","author":"Misale","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1093\/annonc\/mdw235_bb0490","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1200\/JCO.2009.24.6116","article-title":"Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer","volume":"28","author":"Bardelli","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0495","doi-asserted-by":"crossref","first-page":"e1004271","DOI":"10.1371\/journal.pgen.1004271","article-title":"Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing","volume":"10","author":"Mohan","year":"2014","journal-title":"PLoS Genet"},{"key":"10.1093\/annonc\/mdw235_bb0500","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002442","article-title":"Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab","volume":"3","author":"Yonesaka","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1093\/annonc\/mdw235_bb0505","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1158\/2159-8290.CD-11-0109","article-title":"A molecularly annotated platform of patient-derived xenografts (\u2018xenopatients\u2019) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer","volume":"1","author":"Bertotti","year":"2011","journal-title":"Cancer Discov"},{"key":"10.1093\/annonc\/mdw235_bb0510","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","article-title":"Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study","volume":"28","author":"Douillard","year":"2010","journal-title":"J Clin Oncol"},{"issue":"Suppl 3","key":"10.1093\/annonc\/mdw235_bb0515","article-title":"Analysis of KRAS\/NRAS and BRAF mutations in FIRE-3","volume":"49","author":"Stintzing","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdw235_bb0520","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/ijc.28106","article-title":"KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy","volume":"133","author":"Valtorta","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdw235_bb0525","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/gcc.20854","article-title":"Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer","volume":"50","author":"Vaughn","year":"2011","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1093\/annonc\/mdw235_bb0530","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1038\/onc.2013.244","article-title":"Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology","volume":"33","author":"Ogino","year":"2014","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mdw235_bb0535","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1158\/0008-5472.CAN-07-5659","article-title":"PIK3CA mutation\/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab","volume":"68","author":"Jhawer","year":"2008","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdw235_bb0540","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1158\/1078-0432.CCR-13-0606","article-title":"PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer\u2014results from NCIC CTG\/AGITG CO.17","volume":"20","author":"Karapetis","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw235_bb0545","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1158\/1078-0432.CCR-08-2961","article-title":"PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer","volume":"15","author":"Prenen","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw235_bb0550","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1158\/0008-5472.CAN-08-2466","article-title":"PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies","volume":"69","author":"Sartore-Bianchi","year":"2009","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdw235_bb0555","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1136\/gutjnl-2012-302423","article-title":"A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction","volume":"62","author":"Tian","year":"2013","journal-title":"Gut"},{"key":"10.1093\/annonc\/mdw235_bb0560","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/nature11156","article-title":"Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer","volume":"486","author":"Misale","year":"2012","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdw235_bb0565","doi-asserted-by":"crossref","first-page":"5924","DOI":"10.1200\/JCO.2008.21.6796","article-title":"Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer","volume":"27","author":"Laurent-Puig","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0570","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1158\/2159-8290.CD-14-1211","article-title":"HER2 activating mutations are targets for colorectal cancer treatment","volume":"5","author":"Kavuri","year":"2015","journal-title":"Cancer Discov"},{"issue":"15 Suppl","key":"10.1093\/annonc\/mdw235_bb0575","article-title":"Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): the HERACLES trial","volume":"33","author":"Siena","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0580","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1093\/annonc\/mdu149","article-title":"Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis","volume":"25","author":"Juo","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0585","doi-asserted-by":"crossref","first-page":"djt322","DOI":"10.1093\/jnci\/djt322","article-title":"Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer","volume":"106","author":"Moutinho","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdw235_bb0590","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1200\/JCO.2007.15.8923","article-title":"Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer","volume":"26","author":"Cohen","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0595","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2012.45.2011","article-title":"Liquid biopsies: genotyping circulating tumor DNA","volume":"32","author":"Diaz","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0600","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/s13059-014-0449-4","article-title":"Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance","volume":"15","author":"Siravegna","year":"2014","journal-title":"Genome Biol"},{"key":"10.1093\/annonc\/mdw235_bb0605","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nm.2609","article-title":"Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer","volume":"18","author":"Montagut","year":"2012","journal-title":"Nat Med"},{"key":"10.1093\/annonc\/mdw235_bb0610","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11568-011-9149-2","article-title":"Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours","volume":"4","author":"Aung","year":"2010","journal-title":"Hugo J"},{"key":"10.1093\/annonc\/mdw235_bb0615","doi-asserted-by":"crossref","first-page":"224ra224","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1093\/annonc\/mdw235_bb0620","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa1213261","article-title":"Analysis of circulating tumor DNA to monitor metastatic breast cancer","volume":"368","author":"Dawson","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw235_bb0625","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/annonc\/mdu239","article-title":"Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle","volume":"25","author":"De Mattos-Arruda","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0630","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature11219","article-title":"The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers","volume":"486","author":"Diaz","year":"2012","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdw235_bb0635","doi-asserted-by":"crossref","first-page":"136ra168","DOI":"10.1126\/scitranslmed.3003726","article-title":"Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA","volume":"4","author":"Forshew","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1093\/annonc\/mdw235_bb0640","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.mrrev.2006.11.002","article-title":"Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance","volume":"635","author":"Gormally","year":"2007","journal-title":"Mutat Res"},{"key":"10.1093\/annonc\/mdw235_bb0645","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-11-2696","article-title":"Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood","volume":"18","author":"Higgins","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw235_bb0650","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature12065","article-title":"Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA","volume":"497","author":"Murtaza","year":"2013","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdw235_bb0655","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm.3519","article-title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage","volume":"20","author":"Newman","year":"2014","journal-title":"Nat Med"},{"key":"10.1093\/annonc\/mdw235_bb0660","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1158\/1078-0432.CCR-11-3148","article-title":"Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib","volume":"18","author":"Punnoose","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw235_bb0665","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nrc3066","article-title":"Cell-free nucleic acids as biomarkers in cancer patients","volume":"11","author":"Schwarzenbach","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1093\/annonc\/mdw235_bb0670","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1373\/clinchem.2013.206359","article-title":"Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients","volume":"59","author":"Taly","year":"2013","journal-title":"Clin Chem"},{"key":"10.1093\/annonc\/mdw235_bb0675","doi-asserted-by":"crossref","first-page":"7808","DOI":"10.1158\/1078-0432.CCR-11-1712","article-title":"Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas","volume":"17","author":"Taniguchi","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw235_bb0680","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/nm.3511","article-title":"Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA","volume":"20","author":"Thierry","year":"2014","journal-title":"Nat Med"},{"key":"10.1093\/annonc\/mdw235_bb0685","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1186\/s12885-015-1437-0","article-title":"A microRNA molecular modeling extension for prediction of colorectal cancer treatment","volume":"15","author":"Li","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1093\/annonc\/mdw235_bb0690","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1093\/annonc\/mdu230","article-title":"Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial","volume":"25","author":"Ciardiello","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0695","doi-asserted-by":"crossref","first-page":"e1001453","DOI":"10.1371\/journal.pmed.1001453","article-title":"Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value","volume":"10","author":"Marisa","year":"2013","journal-title":"PLoS Med"},{"key":"10.1093\/annonc\/mdw235_bb0700","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat Med"},{"key":"10.1093\/annonc\/mdw235_bb0705","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.2217\/fon.14.125","article-title":"Shifting sands: adapting the multidisciplinary team model to technological and organizational innovations in cancer care","volume":"10","author":"Prades","year":"2014","journal-title":"Future Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0710","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1007\/s00464-014-3545-3","article-title":"Decision-making in Colorectal Cancer Tumor Board meetings: results of a prospective observational assessment","volume":"28","author":"Shah","year":"2014","journal-title":"Surg Endosc"},{"key":"10.1093\/annonc\/mdw235_bb0715","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.healthpol.2014.09.006","article-title":"Is it worth reorganising cancer services on the basis of multidisciplinary teams (MDTs)? A systematic review of the objectives and organisation of MDTs and their impact on patient outcomes","volume":"119","author":"Prades","year":"2015","journal-title":"Health Policy"},{"key":"10.1093\/annonc\/mdw235_bb0720","first-page":"1074","article-title":"Colorectal cancer patients with oligometastatic liver disease: what is the optimal approach?","volume":"27","author":"Weiser","year":"2013","journal-title":"Oncology (Williston Park)"},{"key":"10.1093\/annonc\/mdw235_bb0725","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.clcc.2012.06.004","article-title":"Survival differences in patients with metastatic colorectal cancer and with single site metastatic disease at initial presentation: results from South Australian clinical registry for advanced colorectal cancer","volume":"11","author":"Khattak","year":"2012","journal-title":"Clin Colorectal Cancer"},{"key":"10.1093\/annonc\/mdw235_bb0730","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1743-7563.2011.01458.x","article-title":"Watchful waiting\u2019 for metastatic colorectal cancer, antediluvian or an option to be considered again?","volume":"8","author":"Price","year":"2012","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0735","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1002\/cncr.28729","article-title":"BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer","volume":"120","author":"Yaeger","year":"2014","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdw235_bb0740","first-page":"1741","article-title":"Expression of thymidylate synthase in liver and lung metastases of colorectal cancer and their matched primary tumours","volume":"28","author":"Ohrling","year":"2008","journal-title":"Anticancer Res"},{"key":"10.1093\/annonc\/mdw235_bb0745","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1634\/theoncologist.2012-0121","article-title":"The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus","volume":"17","author":"Adam","year":"2012","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdw235_bb0750","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1056\/NEJMra065156","article-title":"Strategies for safer liver surgery and partial liver transplantation","volume":"356","author":"Clavien","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw235_bb0755","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/bjs.5719","article-title":"Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases","volume":"94","author":"Zorzi","year":"2007","journal-title":"Br J Surg"},{"key":"10.1093\/annonc\/mdw235_bb0760","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.suronc.2014.02.002","article-title":"Controversies in the oncosurgical management of liver limited stage IV colorectal cancer","volume":"23","author":"Jones","year":"2014","journal-title":"Surg Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0765","first-page":"283","article-title":"Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors","volume":"4","author":"Kanas","year":"2012","journal-title":"Clin Epidemiol"},{"key":"10.1093\/annonc\/mdw235_bb0770","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00000658-199909000-00004","article-title":"Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases","volume":"230","author":"Fong","year":"1999","journal-title":"Ann Surg"},{"key":"10.1093\/annonc\/mdw235_bb0775","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jmri.22010","article-title":"Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and meta-analysis","volume":"31","author":"Floriani","year":"2010","journal-title":"J Magn Reson Imaging"},{"key":"10.1093\/annonc\/mdw235_bb0780","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1007\/s11547-010-0506-3","article-title":"Characterisation of focal liver lesions undetermined at grey-scale US: contrast-enhanced US versus 64-row MDCT and MRI with liver-specific contrast agent","volume":"115","author":"Bartolotta","year":"2010","journal-title":"Radiol Med"},{"key":"10.1093\/annonc\/mdw235_bb0785","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1148\/radiol.10100729","article-title":"Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and\/or FDG PET\/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment","volume":"257","author":"Niekel","year":"2010","journal-title":"Radiology"},{"key":"10.1093\/annonc\/mdw235_bb0790","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/bjs.9465","article-title":"Randomized multicentre trial of gadoxetic acid-enhanced MRI versus conventional MRI or CT in the staging of colorectal cancer liver metastases","volume":"101","author":"Zech","year":"2014","journal-title":"Br J Surg"},{"key":"10.1093\/annonc\/mdw235_bb0795","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1093\/annonc\/mdr554","article-title":"Serial FDG-PET\/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy","volume":"23","author":"Hendlisz","year":"2012","journal-title":"Ann Oncol"},{"issue":"Suppl","key":"10.1093\/annonc\/mdw235_bb0800","article-title":"An Ontario Clinical Oncology Group (OCOG) randomized controlled trial (RCT) assessing FDG PET\/CT in resectable liver colorectal adenocarcinoma metastases (CAM)","volume":"29","author":"Moulton","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0805","first-page":"471","article-title":"Clinical impact of FDG-PET\/CT on colorectal cancer staging and treatment strategy","volume":"4","author":"Petersen","year":"2014","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"10.1093\/annonc\/mdw235_bb0810","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s00259-014-2930-4","article-title":"Diagnostic accuracy and impact on management of (18)F-FDG PET and PET\/CT in colorectal liver metastasis: a meta-analysis and systematic review","volume":"42","author":"Maffione","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1093\/annonc\/mdw235_bb0815","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1200\/JCO.2007.11.0833","article-title":"Actual 10-year survival after resection of colorectal liver metastases defines cure","volume":"25","author":"Tomlinson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0820","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S1470-2045(13)70447-9","article-title":"Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial","volume":"14","author":"Nordlinger","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0825","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0140-6736(08)60455-9","article-title":"Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial","volume":"371","author":"Nordlinger","year":"2008","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdw235_bb0830","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1470-2045(14)70105-6","article-title":"Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial","volume":"15","author":"Primrose","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0835","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1200\/JCO.2008.17.3781","article-title":"Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials","volume":"26","author":"Mitry","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0840","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1093\/annonc\/mdn769","article-title":"Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer","volume":"20","author":"Kemeny","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0845","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/01.sla.0000141198.92114.f6","article-title":"Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival","volume":"240","author":"Adam","year":"2004","journal-title":"Ann Surg"},{"issue":"15 Suppl","key":"10.1093\/annonc\/mdw235_bb0850","article-title":"Impact of the type and modalities of preoperative chemotherapy on the outcome of liver resection for colorectal metastases","volume":"29","author":"Adam","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0855","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1001\/jama.2009.1755","article-title":"Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases","volume":"302","author":"Chun","year":"2009","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdw235_bb0860","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1097\/SLA.0b013e3181fcf3e3","article-title":"Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases?","volume":"252","author":"Adam","year":"2010","journal-title":"Ann Surg"},{"key":"10.1093\/annonc\/mdw235_bb0865","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/annonc\/mdn735","article-title":"Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel","volume":"20","author":"Nordlinger","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0870","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.ejca.2007.07.017","article-title":"Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group","volume":"43","author":"Nordlinger","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdw235_bb0875","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.ejca.2006.04.012","article-title":"Towards a pan-European consensus on the treatment of patients with colorectal liver metastases","volume":"42","author":"Van Cutsem","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdw235_bb0880","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/annonc\/mdi246","article-title":"Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates","volume":"16","author":"Folprecht","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0885","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1470-2045(09)70330-4","article-title":"Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial","volume":"11","author":"Folprecht","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0890","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1200\/JCO.2012.44.8308","article-title":"Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases","volume":"31","author":"Ye","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0895","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/annonc\/mdu580","article-title":"Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial","volume":"26","author":"Gruenberger","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0900","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S1470-2045(10)70175-3","article-title":"Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial","volume":"11","author":"Masi","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0905","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1093\/annonc\/mdu088","article-title":"Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX\/cetuximab or FOLFIRI\/cetuximab in a multidisciplinary concept (CELIM study)","volume":"25","author":"Folprecht","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0910","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1200\/JCO.2006.09.0928","volume":"25","author":"Falcone","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0915","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1403108","article-title":"Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer","volume":"371","author":"Loupakis","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw235_bb0920","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/annonc\/mdu141","article-title":"Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer","volume":"25","author":"Douillard","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0925","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/sj.bjc.6605259","article-title":"Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial","volume":"101","author":"Okines","year":"2009","journal-title":"Br J Cancer"},{"issue":"15 Suppl","key":"10.1093\/annonc\/mdw235_bb0930","volume":"32","author":"Venook","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0935","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1200\/JCO.2012.42.8532","article-title":"Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab","volume":"31","author":"Piessevaux","year":"2013","journal-title":"J Clin Oncol"},{"issue":"Suppl 4","key":"10.1093\/annonc\/mdw235_bb0940","article-title":"Validating the prognostic relevance of initial change in tumor size using a series of therapeutic regimens for patients with metastatic colorectal cancer (mCRC)","volume":"30","author":"Mansmann","year":"2012","journal-title":"J Clin Oncol"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdw235_bb0945","article-title":"Improved early prediction of individual prognosis for patients with mCRC: joint modeling of tumor shrinkage with volume data for PFS and OS","volume":"30","author":"Mansmann","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0950","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/annonc\/mdp011","article-title":"Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial)","volume":"20","author":"Piessevaux","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0955","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1093\/annonc\/mdv112","article-title":"Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest","volume":"26","author":"Cremolini","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0960","first-page":"291","article-title":"FOLFOXIRI and bevacizumab for metastatic colorectal cancer","volume":"372","author":"Cremolini","year":"2015","journal-title":"N Engl J Med"},{"issue":"Suppl 4","key":"10.1093\/annonc\/mdw235_bb0965","article-title":"FOLFOXIRI\/bevacizumab versus FOLFIRI\/bevacizumab as first-line treatment in unresectable metastatic colorectal cancer: results of phase III TRIBE trial by GONO Group","volume":"24","author":"Cremolini","year":"2014","journal-title":"Ann Oncol"},{"issue":"Suppl 5","key":"10.1093\/annonc\/mdw235_bb0970","article-title":"Independent radiological evaluation of objective response, early tumor shrinkage, and depth of response in FIRE-3 (AIO KRK-0306) in the final RAS evaluable population","volume":"25","author":"Stintzing","year":"2014","journal-title":"Ann Oncol"},{"issue":"Suppl 4","key":"10.1093\/annonc\/mdw235_bb0975","article-title":"First-line treatment with modified FOLFOX6 (mFOLFOX6) + panitumumab or bevacizumab in patients with RAS\/BRAF wild-type (WT) metastatic colorectal carcinoma (mCRC)","volume":"26","author":"Rivera","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0980","article-title":"Efficacy and toxicity of hepatic intra-arterial drug-eluting (irinotecan) bead (DEBIRI) therapy in irinotecan-refractory unresectable colorectal liver metastases","author":"Bhutiani","year":"2015","journal-title":"World J Surg"},{"key":"10.1093\/annonc\/mdw235_bb0985","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2217\/fon.15.3","article-title":"A review of conventional and drug-eluting chemoembolization in the treatment of colorectal liver metastases: principles and proof","volume":"11","author":"Liu","year":"2015","journal-title":"Future Oncol"},{"key":"10.1093\/annonc\/mdw235_bb0990","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1002\/cncr.29534","article-title":"Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis","volume":"121","author":"Martin","year":"2015","journal-title":"Cancer"},{"issue":"15 Suppl","key":"10.1093\/annonc\/mdw235_bb0995","article-title":"Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): long-term survival results of a randomized phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC)","volume":"33","author":"Ruers","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1000","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.ejca.2013.12.008","article-title":"Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983","volume":"50","author":"Tanis","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdw235_bb1005","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1093\/annonc\/mds053","article-title":"Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004)","volume":"23","author":"Ruers","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1010","doi-asserted-by":"crossref","first-page":"e114404","DOI":"10.1371\/journal.pone.0114404","article-title":"Combined ablation and resection (CARe) as an effective parenchymal sparing treatment for extensive colorectal liver metastases","volume":"9","author":"Evrard","year":"2014","journal-title":"PLoS One"},{"key":"10.1093\/annonc\/mdw235_bb1015","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S1470-2045(08)70155-4","article-title":"Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study)","volume":"9","author":"Lencioni","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1020","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.clcc.2012.07.003","article-title":"Treatment of pulmonary colorectal metastases by radiofrequency ablation","volume":"12","author":"Petre","year":"2013","journal-title":"Clin Colorectal Cancer"},{"key":"10.1093\/annonc\/mdw235_bb1025","doi-asserted-by":"crossref","first-page":"W576","DOI":"10.2214\/AJR.11.6408","article-title":"Complications after 1000 lung radiofrequency ablation sessions in 420 patients: a single center's experiences","volume":"197","author":"Kashima","year":"2011","journal-title":"Am J Roentgenol"},{"key":"10.1093\/annonc\/mdw235_bb1030","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ctrv.2013.05.004","article-title":"What to choose as radical local treatment for lung metastases from colo-rectal cancer: surgery or radiofrequency ablation?","volume":"40","author":"Schlijper","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1093\/annonc\/mdw235_bb1035","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ijrobp.2009.09.026","article-title":"Local response and impact on survival after local ablation of liver metastases from colorectal carcinoma by computed tomography-guided high-dose-rate brachytherapy","volume":"78","author":"Ricke","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdw235_bb1040","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s00066-014-0714-1","article-title":"Stereotactic body radiotherapy for liver tumors: principles and practical guidelines of the DEGRO Working Group on Stereotactic Radiotherapy","volume":"190","author":"Sterzing","year":"2014","journal-title":"Strahlenther Onkol"},{"key":"10.1093\/annonc\/mdw235_bb1045","first-page":"316","article-title":"Percutaneous CT-guided high-dose brachytherapy (CT-HDRBT) ablation of primary and metastatic lung tumors in nonsurgical candidates","volume":"184","author":"Collettini","year":"2012","journal-title":"Rofo"},{"key":"10.1093\/annonc\/mdw235_bb1050","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1186\/1471-2407-14-619","article-title":"Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach","volume":"14","author":"Comito","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1093\/annonc\/mdw235_bb1055","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7785\/tcrt.2012.500355","article-title":"Outcomes of single fraction stereotactic ablative radiotherapy for lung metastases","volume":"13","author":"Filippi","year":"2014","journal-title":"Technol Cancer Res Treat"},{"key":"10.1093\/annonc\/mdw235_bb1060","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/JTO.0b013e318208c7a3","article-title":"Computed tomography-guided interstitial high-dose-rate brachytherapy in the local treatment of primary and secondary intrathoracic malignancies","volume":"6","author":"Tselis","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1065","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s00066-008-1718-5","article-title":"CT-guided interstitial brachytherapy of primary and secondary lung malignancies: results of a prospective phase II trial","volume":"184","author":"Peters","year":"2008","journal-title":"Strahlenther Onkol"},{"key":"10.1093\/annonc\/mdw235_bb1070","doi-asserted-by":"crossref","first-page":"861","DOI":"10.3109\/02841869509127197","article-title":"Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients","volume":"34","author":"Blomgren","year":"1995","journal-title":"Acta Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1075","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.ijrobp.2003.08.012","article-title":"Univariate analysis of factors correlated with tumor control probability of three-dimensional conformal hypofractionated high-dose radiotherapy for small pulmonary or hepatic tumors","volume":"58","author":"Wada","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdw235_bb1080","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1080\/02841860600904821","article-title":"Stereotactic radiotherapy of primary liver cancer and hepatic metastases","volume":"45","author":"Wulf","year":"2006","journal-title":"Acta Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1085","first-page":"3381","article-title":"Image-guided robotic stereotactic radiosurgery for unresectable liver metastases: preliminary results","volume":"29","author":"Ambrosino","year":"2009","journal-title":"Anticancer Res"},{"key":"10.1093\/annonc\/mdw235_bb1090","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ijrobp.2009.08.020","article-title":"Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies","volume":"78","author":"Goodman","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdw235_bb1095","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1080\/02841860600904854","article-title":"Phase II study on stereotactic body radiotherapy of colorectal metastases","volume":"45","author":"Hoyer","year":"2006","journal-title":"Acta Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1100","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1200\/JCO.2008.20.0600","article-title":"Phase I study of individualized stereotactic body radiotherapy of liver metastases","volume":"27","author":"Lee","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1105","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1080\/02841860600897934","article-title":"Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase i-ii study","volume":"45","author":"Mendez Romero","year":"2006","journal-title":"Acta Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1110","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1200\/JCO.2008.19.6329","article-title":"Multi-institutional phase I\/II trial of stereotactic body radiation therapy for liver metastases","volume":"27","author":"Rusthoven","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1115","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijrobp.2012.12.021","article-title":"Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial","volume":"86","author":"Scorsetti","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdw235_bb1120","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/1748-717X-7-164","article-title":"A single-institution study of stereotactic body radiotherapy for patients with unresectable visceral pulmonary or hepatic oligometastases","volume":"7","author":"Fumagalli","year":"2012","journal-title":"Radiat Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1125","first-page":"1387","article-title":"Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study","volume":"32","author":"Fiorentini","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1093\/annonc\/mdw235_bb1130","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1200\/JCO.2010.28.5643","article-title":"Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy","volume":"28","author":"Hendlisz","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1135","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1200\/JCO.2015.66.1181","article-title":"SIRFLOX: randomized phase iii trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer","volume":"34","author":"van Hazel","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1140","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1002\/hep.26947","article-title":"Left-liver hypertrophy after therapeutic right-liver radioembolization is substantial but less than after portal vein embolization","volume":"59","author":"Garlipp","year":"2014","journal-title":"Hepatology"},{"key":"10.1093\/annonc\/mdw235_bb1145","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1245\/s10434-009-0487-4","article-title":"A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin","volume":"16","author":"Cao","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1150","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/PPO.0b013e3181a58d67","article-title":"Management of peritoneal carcinomatosis from colorectal cancer: current state of practice","volume":"15","author":"Cotte","year":"2009","journal-title":"Cancer J"},{"key":"10.1093\/annonc\/mdw235_bb1155","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1200\/JCO.2008.19.7160","article-title":"Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin","volume":"27","author":"Elias","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1160","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.ejso.2014.06.006","article-title":"Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin","volume":"40","author":"Elias","year":"2014","journal-title":"Eur J Surg Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1165","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1245\/s10434-013-3061-z","article-title":"Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States","volume":"21","author":"Turaga","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1170","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/jso.23728","article-title":"The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with mitomycin C versus oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery","volume":"110","author":"Prada-Villaverde","year":"2014","journal-title":"J Surg Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1175","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"18","author":"de Gramont","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1180","first-page":"51","article-title":"Irinotecan and high-dose fluorouracil\/leucovorin for metastatic colorectal cancer","volume":"14","author":"Douillard","year":"2000","journal-title":"Oncology (Williston Park)"},{"key":"10.1093\/annonc\/mdw235_bb1185","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1200\/JCO.1997.15.2.808","article-title":"Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study","volume":"15","author":"de Gramont","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1190","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1200\/JCO.1998.16.11.3537","article-title":"Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors","volume":"16","author":"Levy","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1195","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/sj.bjc.6601676","article-title":"Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials","volume":"90","author":"Van Cutsem","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdw235_bb1200","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1200\/JCO.2007.14.9898","article-title":"Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer","volume":"26","author":"Cassidy","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1205","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.1200\/JCO.2007.11.3357","article-title":"Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study","volume":"25","author":"Fuchs","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1210","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/annonc\/mdm544","article-title":"Irinotecan combined with infusional 5-fluorouracil\/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015","volume":"19","author":"Kohne","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1215","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1093\/annonc\/mdt028","article-title":"Capecitabine\/irinotecan or capecitabine\/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group","volume":"24","author":"Schmiegel","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1220","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1200\/JCO.2010.31.1936","article-title":"Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104\u2014a randomized trial of the German AIO CRC study group","volume":"29","author":"Moosmann","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1225","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw235_bb1230","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study","volume":"26","author":"Saltz","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1235","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/sj.bjc.6603011","volume":"94","author":"Souglakos","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdw235_bb1240","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S1470-2045(13)70154-2","article-title":"Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial","volume":"14","author":"Cunningham","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1245","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000163850","article-title":"Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk","volume":"75","author":"Kabbinavar","year":"2008","journal-title":"Oncology"},{"key":"10.1093\/annonc\/mdw235_bb1250","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1200\/JCO.2009.27.7723","article-title":"Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study","volume":"28","author":"Tebbutt","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1255","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1093\/annonc\/mdv130","article-title":"Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial","volume":"26","author":"Passardi","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1260","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/bjc.2011.594","article-title":"Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable\/metastatic colorectal cancer (mCRC)","volume":"106","author":"Souglakos","year":"2012","journal-title":"Br J Cancer"},{"issue":"15 Suppl","key":"10.1093\/annonc\/mdw235_bb1265","article-title":"A randomized phase III trial of mFOLFOX6 plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment for metastatic colorectal cancer: West Japan Oncology Group study 4407G (WJOG4407G)","volume":"32","author":"Yamazaki","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1270","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1634\/theoncologist.2009-0071","article-title":"Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study","volume":"14","author":"Kozloff","year":"2009","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdw235_bb1275","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1093\/annonc\/mdp233","article-title":"Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study","volume":"20","author":"Van Cutsem","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1280","unstructured":"European Medicines Agency. CHMP summary of opinion\u2014erbitux. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion\/human\/000558\/WC500155463.pdf (6 January 2015, date last accessed)."},{"key":"10.1093\/annonc\/mdw235_bb1285","unstructured":"European Medicines Agency. CHMP summary of opinion\u2014vectibix. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion\/human\/000741\/WC500144827.pdf (6 January 2015, date last accessed)."},{"key":"10.1093\/annonc\/mdw235_bb1290","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2004.11.037","article-title":"Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment","volume":"22","author":"Grothey","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1295","doi-asserted-by":"crossref","first-page":"9441","DOI":"10.1200\/JCO.2005.04.4792","article-title":"Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line","volume":"23","author":"Grothey","year":"2005","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"10.1093\/annonc\/mdw235_bb1300","article-title":"Independent radiological evaluation of objective response, early tumor shrinkage, and depth of response in FIRE-3 (AIO KRK-0306)","volume":"25","author":"Heinemann","year":"2014","journal-title":"Ann Oncol"},{"issue":"Suppl 5","key":"10.1093\/annonc\/mdw235_bb1305","volume":"25","author":"Lenz","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1310","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(03)12461-0","article-title":"Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial","volume":"361","author":"Maughan","year":"2003","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdw235_bb1315","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1093\/annonc\/mdq580","article-title":"Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised \u2018GISCAD\u2019 trial","volume":"22","author":"Labianca","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1320","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2005.03.0106","article-title":"OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer\u2014a GERCOR study","volume":"24","author":"Tournigand","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1325","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S1470-2045(11)70102-4","article-title":"Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial","volume":"12","author":"Adams","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1330","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1200\/JCO.2009.23.4344","article-title":"Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study","volume":"27","author":"Chibaudel","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1335","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(15)00216-8","article-title":"Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial","volume":"16","author":"Tournigand","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1340","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1634\/theoncologist.2011-0249","article-title":"First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study","volume":"17","author":"Diaz-Rubio","year":"2012","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdw235_bb1345","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/S1470-2045(15)00042-X","article-title":"Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial","volume":"16","author":"Hegewisch-Becker","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1350","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/annonc\/mdv011","article-title":"Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41\/06)","volume":"26","author":"Koeberle","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1355","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(14)62004-3","article-title":"Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group","volume":"385","author":"Simkens","year":"2015","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdw235_bb1360","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(14)70106-8","article-title":"Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial","volume":"15","author":"Wasan","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1365","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1093\/annonc\/mdt236","article-title":"A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial","volume":"24","author":"Johnsson","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1370","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/bjc.2015.299","article-title":"Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer","volume":"113","author":"Stein","year":"2015","journal-title":"Br J Cancer"},{"issue":"Suppl 4","key":"10.1093\/annonc\/mdw235_bb1375","volume":"25","author":"Garcia Alfonso","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1380","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(98)02309-5","article-title":"Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer","volume":"352","author":"Cunningham","year":"1998","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdw235_bb1385","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/annonc\/mdf259","article-title":"Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study","volume":"13","author":"Rougier","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1390","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(98)03085-2","article-title":"Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer","volume":"352","author":"Rougier","year":"1998","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdw235_bb1395","doi-asserted-by":"crossref","first-page":"4544","DOI":"10.1200\/JCO.2008.17.1249","article-title":"Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma","volume":"26","author":"Haller","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1400","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0140-6736(07)61086-1","article-title":"Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial","volume":"370","author":"Koopman","year":"2007","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdw235_bb1405","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(07)61087-3","article-title":"Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial","volume":"370","author":"Seymour","year":"2007","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdw235_bb1410","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","article-title":"FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study","volume":"22","author":"Tournigand","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1415","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","article-title":"Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200","volume":"25","author":"Giantonio","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1420","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","article-title":"Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial","volume":"14","author":"Bennouna","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1425","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s12032-013-0486-y","article-title":"FOLFIRI + bevacizumab as second-line therapy for metastatic colorectal cancer pretreated with oxaliplatin: a pooled analysis of published trials","volume":"30","author":"Beretta","year":"2013","journal-title":"Med Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1430","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1186\/1471-2407-9-347","article-title":"Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study","volume":"9","author":"Lievre","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1093\/annonc\/mdw235_bb1435","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1093\/annonc\/mdv012","article-title":"Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial","volume":"26","author":"Masi","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1440","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","article-title":"Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen","volume":"30","author":"Van Cutsem","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1445","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ejca.2013.09.013","article-title":"Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial","volume":"50","author":"Tabernero","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdw235_bb1450","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1470-2045(15)70127-0","volume":"16","author":"Tabernero","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1455","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1200\/JCO.2007.13.1193","article-title":"EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer","volume":"26","author":"Sobrero","year":"2008","journal-title":"J Clin Oncol"},{"issue":"Suppl S3","key":"10.1093\/annonc\/mdw235_bb1460","volume":"51","author":"Cascinu","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdw235_bb1465","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.clcc.2014.12.009","article-title":"SPIRITT: a randomized, multicenter, phase II study of panitumumab with FOLFIRI and bevacizumab with FOLFIRI as second-line treatment in patients with unresectable wild type KRAS metastatic colorectal cancer","volume":"14","author":"Hecht","year":"2015","journal-title":"Clin Colorectal Cancer"},{"key":"10.1093\/annonc\/mdw235_bb1470","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw235_bb1475","first-page":"53","article-title":"Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer","volume":"6","author":"Geva","year":"2013","journal-title":"Onco Targets Ther"},{"key":"10.1093\/annonc\/mdw235_bb1480","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/cncr.22915","article-title":"Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer","volume":"110","author":"Hecht","year":"2007","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdw235_bb1485","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S1470-2045(14)70118-4","article-title":"Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study","volume":"15","author":"Price","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1490","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdw235_bb1495","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","article-title":"Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"16","author":"Li","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1500","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw235_bb1505","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S1470-2045(12)70345-5","article-title":"TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial","volume":"13","author":"Yoshino","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1510","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/annonc\/mdu253","article-title":"Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013","volume":"26","author":"Papamichael","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1515","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.2007.13.7679","article-title":"Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer","volume":"26","author":"Gruenberger","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw235_bb1520","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/sj.bjc.6605940","article-title":"Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial","volume":"103","author":"Garufi","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdw235_bb1525","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1093\/annonc\/mdq714","article-title":"A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection","volume":"22","author":"Wong","year":"2011","journal-title":"Ann Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419347544?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419347544?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/27\/8\/1386\/6680767\/mdw235.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T04:00:22Z","timestamp":1624680022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419347544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":304,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S0923753419347544"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdw235","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726487499.793550893","asserted-by":"object"}]},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]}}}